Angew Chem Int Ed Engl 55(27):76067630 Bianco AC, Salvatore D, Gereben B et al (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases
Wegovy Just like with semaglutide, tirzepatide has two brand names: Mounjaro: FDA-approved for Type 2 Diabetes Maximum dose: 15 mg weekly Prescribed primarily for blood sugar control Zepbound: FDA-approved for weight management Same maximum dose: 15 mg weekly Marketed for obesity treatment The drugs are chemically identical, but the legal considerations mirror the Ozempic/Wegovy distinction: Different labels and warnings Different approved uses Potential off-label prescribing Different marketing claims Case Example: Tirzepatide Injury Patient Profile: 52-year-old woman with BMI 34 No diabetes, seeking weight loss Prescribed Zepbound, escalated to 15 mg Timeline: Month 1-3: Excellent weight loss (25 lbs), manageable nausea Month 4: Persistent vomiting began Month 5: Unable to eat solid food, lost 15 more lbs Month 6: Diagnosed with severe gastroparesis via gastric emptying scan Current: 12 months post-discontinuation, still cannot eat normally, requires liquid diet Legal Claim: Inadequate warnings about permanence of gastroparesis Marketing emphasized dramatic weight loss without proper risk disclosure Failure to inform that condition might not resolve after stopping Damages include ongoing medical care, lost wages, diminished quality of life 5
Patients should be aware of safety considerations when seeking to reduce costs
The wave of closures reflects a combination of increased FDA enforcement activity, regulatory pressure from the peptide reclassification process, and a general tightening of the research chemical market
Semaglutide and Muscle Pain: Possible Causes Electrolyte Disbalances Electrolyte Disbalances The changes in the balance of fluids and useful substances occur due to the impact of Semaglutide on the digestive system
Weight loss often begins in the first week
